#CNBC Novo Nordisk CEO Mike Doustdar on $10B Metsera bid, expanding use of obesity drugs

Novo Nordisk CEO Mike Doustdar on $10B Metsera bid, expanding use of obesity drugs
Novo Nordisk CEO Mike Doustdar joins ‘Squawk Box’ to discuss the company’s quarterly earnings results, the company’s bid for obesity biotech company Metsera, negotiations with the Trump administration to sell some of its obesity drugs to consumers at a lower rate, expanding the use of obesity drug, and more.

Thank you for your support in keeping this website running.💛

View on “Tokyo Trend News”